Results of the citalopram to enhance cognition in Huntington disease trial. - Wikidata - awgldk - TriplyDB

Results of the citalopram to enhance cognition in Huntington disease trial.

Results of the citalopram to enhance cognition in Huntington disease trial.

http://www.wikidata.org/entity/Q37649788

about

Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations.Therapeutic advances in Huntington's Disease.Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?Systematic review of pharmacological treatments for depressive symptoms in Huntington's disease.Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches?Practice Effects and Stability of Neuropsychological and UHDRS Tests Over Short Retest Intervals in Huntington Disease.Advancing pharmacotherapy for treating Huntington's disease: a review of the existing literature.Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts.Huntington's Disease-Update on Treatments.Psychiatric comorbidities in movement disorders.Overstatements in abstract conclusions claiming effectiveness of interventions in psychiatry: A meta-epidemiological investigation.Potential implications of practice effects in Alzheimer's disease prevention trials.Rating scales for cognition in Huntington's disease: Critique and recommendations.Therapy development in Huntington disease: From current strategies to emerging opportunities.Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations

P2860

Q30249645-DB9C94B5-774D-45F8-A83A-F1CA7C35FB41 Q34487604-0EAAF8F1-23AA-4DC3-9294-326025DB1D78 Q35158376-B1064143-389F-40B6-88FF-742B20F9A1FC Q38238894-A4E21905-172B-4100-93CE-55C85EA33337 Q38244078-48C1270A-691F-4431-B55D-C27CA92ED112 Q38402339-3B97C427-9D97-4DD9-83DC-1FEA1926A723 Q38624994-E3452329-4DA1-4990-9601-CC01DB7628C7 Q38792714-CC50C9CD-7E79-4A1F-9B47-C3E5076416A6 Q39190617-4814C95F-ED5D-411C-98F8-53D02E342A31 Q39417632-62D88BFA-F49E-4F90-AFDD-FC1780FE29FB Q41140653-F9792EBA-B909-4500-B17E-C5020903D580 Q46493022-567691A5-C5A8-40E6-A963-B97C946C31BE Q47219147-FF4F3617-5C52-44CE-AFEC-5718B4E7D50A Q53716390-F53CB54D-9059-43B5-A4F4-51AA5E3AC04B Q58574520-70DCA4B6-C9B1-462C-9153-2840E6469930

P2860

Results of the citalopram to enhance cognition in Huntington disease trial.

http://www.wikidata.org/entity/Q37649788

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 27 December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Results of the citalopram to enhance cognition in Huntington disease trial.

@en

Results of the citalopram to enhance cognition in Huntington disease trial.

@nl

type

label

Results of the citalopram to enhance cognition in Huntington disease trial.

@en

Results of the citalopram to enhance cognition in Huntington disease trial.

@nl

prefLabel

Results of the citalopram to enhance cognition in Huntington disease trial.

@en

Results of the citalopram to enhance cognition in Huntington disease trial.

@nl

P1433

Q37649788-FDCAE242-AE68-4919-80E6-F2438B858785

P1476

Q37649788-4502B1EE-1D40-4FEC-B606-181B56A0C257

P2093

Q37649788-2D73579D-C39D-440B-A126-68BCAD1B49A9

Q37649788-3EC0619B-B87A-4280-9242-904B0753A889

Q37649788-5B51B69A-3BC6-4493-83CB-DC8681577015

Q37649788-7344D19F-15C9-4289-A012-A246ADFF4ED2

Q37649788-C0585FD9-F69D-4E8F-917C-16B0CF6A9CA7

Q37649788-E7E3E541-0433-4382-8F16-F6B5A37E3DB5

Q37649788-F63FD2B2-8FE9-408E-8A63-ACA214C78E85

P2860

Q37649788-144400F0-411E-452F-9175-7A5D45F6408F

Q37649788-242BB518-9058-47C4-882C-B83855A79534

Q37649788-26D3F352-C36A-4ACF-9F52-95A822DDB545

Q37649788-2F7B8669-DBB8-4E2A-9563-E6A9EBC7BD42

Q37649788-3A4C1F3C-E792-4C6D-BECE-A6DAB9371C46

Q37649788-5453AC69-FA86-4A54-A760-444F7E781BBD

Q37649788-5B25501C-0A9C-4FF6-8AEC-67A6B7281303

Q37649788-603A0CCD-F70F-4DAF-8E5B-371AE5D18626

Q37649788-64FD5412-0892-41B6-9EE3-5E0BA979E32B

Q37649788-66F48A55-AA29-4948-BBC3-9D4A695E2091

P304

Q37649788-6E14580D-9001-4EB8-BB50-AB15BD11304D

P31

Q37649788-3AD38ECD-A44D-4F86-9D3D-96C4D8C0EA34

P356

Q37649788-64F3CFE7-9B95-4DE4-87DE-652AF10C6C72

P407

Q37649788-5085DBB9-D090-46F8-9710-C834E26D8069

P433

Q37649788-4E9DE1FA-6939-4087-A93A-768E0BD9FDE1

P478

Q37649788-A9E5AF74-61DE-49E0-8951-FEA300E61AF8

P50

Q37649788-84033607-22FD-479E-A536-BB072103DD47

Q37649788-86B2D26E-2ACF-43E4-9C3C-1883424A73F5

Q37649788-AB11D416-9551-4427-87D1-93426592B538

Q37649788-E2962848-189C-4B0D-86DA-F47A56E11C36

P577

Q37649788-B8D21CF1-26EF-4CC9-9F14-8CD5EEAF121A

P698

Q37649788-E5C5824E-344D-4D56-8E23-095C6CBE8D23

P921

Q37649788-C094123B-2F8C-4218-9060-4942423157A9

P932

Q37649788-1376AB25-C930-491E-9789-E64F790FC992

P356

P1433

Movement Disorders

P1476

Results of the citalopram to enhance cognition in Huntington disease trial.

@en

P2093

Blair Olson

http://www.w3.org/2001/XMLSchema#string

John Caviness

http://www.w3.org/2001/XMLSchema#string

Kevin Biglan

http://www.w3.org/2001/XMLSchema#string

Leigh J Beglinger

http://www.w3.org/2001/XMLSchema#string

Ricardo Jorge

http://www.w3.org/2001/XMLSchema#string

Robert G Robinson

http://www.w3.org/2001/XMLSchema#string

William H Adams

http://www.w3.org/2001/XMLSchema#string

P2860

Antidepressant drug effects and depression severity: a patient-level meta-analysis

Fluoxetine in the treatment of Huntington's disease.

Comparison of executive and visuospatial memory function in Huntington's disease and dementia of Alzheimer type matched for degree of dementia.

Inhibition of tryptophan hydroxylase activity and decreased 5-HT1A receptor binding in a mouse model of Huntington's disease.

Evidence for specific cognitive deficits in preclinical Huntington's disease.

Rate of functional decline in Huntington's disease. Huntington Study Group.

The Neuropsychiatric Inventory: assessing psychopathology in dementia patients.

Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition.

Paroxetine retards disease onset and progression in Huntingtin mutant mice.

Huntington disease: clinical care and evaluation.

P304

401-405

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.25750

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Jess G. Fiedorowicz

Jane S. Paulsen

Douglas R Langbehn

P577

2013-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24375941

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

P932

3960314

http://www.w3.org/2001/XMLSchema#string